| 发明名称 |
METFORMIN-ORLISTAT COMPOSITIONS |
| 摘要 |
This invention provides a combination of a hypoglycemic, metformin, and an irreversible intestinal gastric and pancreatic lipase inhibitor, Orlistat, for a better control of obesity than with the monotherapy used with each of them; this composition provides “low” doses of both drugs to minimize secondary effects and to make use of the synergic effect of both compounds. |
| 申请公布号 |
US2015342921(A1) |
申请公布日期 |
2015.12.03 |
| 申请号 |
US201314648992 |
申请日期 |
2013.11.01 |
| 申请人 |
LANDSTEINER SCIENTIFIC S.A. DE C.V. |
发明人 |
Mondragón Maria Lourdes Garcia;Pacheco Marisol Juana Gomora;Bernal Patricia Maria Rodriguez |
| 分类号 |
A61K31/337;A61K31/155 |
主分类号 |
A61K31/337 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. Pharmaceutical compositions to prevent and treat obesity are so characterized because they contain between 200 and 600 mg of metformin and between 40 and 100 mg of Orlistat; and from 10 to 15% of the total weight of the composition is one or more pharmaceutically acceptable excipients. |
| 地址 |
Distrito Federal MX |
